Compare WYETH LTD with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs SUN PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD SUN PHARMA WYETH LTD/
SUN PHARMA
 
P/E (TTM) x 27.7 20.6 134.7% View Chart
P/BV x 5.3 2.4 221.8% View Chart
Dividend Yield % 1.3 0.7 192.2%  

Financials

 WYETH LTD   SUN PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
SUN PHARMA
Mar-19
WYETH LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044679 153.9%   
Low Rs818375 217.9%   
Sales per share (Unadj.) Rs298.6121.1 246.5%  
Earnings per share (Unadj.) Rs57.213.4 427.9%  
Cash flow per share (Unadj.) Rs58.420.7 282.4%  
Dividends per share (Unadj.) Rs17.002.75 618.2%  
Dividend yield (eoy) %1.80.5 349.9%  
Book value per share (Unadj.) Rs249.5172.6 144.5%  
Shares outstanding (eoy) m22.722,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.4 71.7%   
Avg P/E ratio x16.339.4 41.3%  
P/CF ratio (eoy) x15.925.5 62.6%  
Price / Book Value ratio x3.73.1 122.2%  
Dividend payout %29.720.6 144.5%   
Avg Mkt Cap Rs m21,1571,264,650 1.7%   
No. of employees `0000.517.5 2.8%   
Total wages/salary Rs m40059,671 0.7%   
Avg. sales/employee Rs Th13,787.416,608.1 83.0%   
Avg. wages/employee Rs Th813.03,409.6 23.8%   
Avg. net profit/employee Rs Th2,643.31,833.8 144.1%   
INCOME DATA
Net Sales Rs m6,783290,659 2.3%  
Other income Rs m35310,255 3.4%   
Total revenues Rs m7,136300,914 2.4%   
Gross profit Rs m1,61763,076 2.6%  
Depreciation Rs m2717,533 0.2%   
Interest Rs m65,553 0.1%   
Profit before tax Rs m1,93850,246 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5-12,144 0.0%   
Tax Rs m6326,009 10.5%   
Profit after tax Rs m1,30132,093 4.1%  
Gross profit margin %23.821.7 109.9%  
Effective tax rate %32.612.0 272.8%   
Net profit margin %19.211.0 173.6%  
BALANCE SHEET DATA
Current assets Rs m6,984310,692 2.2%   
Current liabilities Rs m2,056173,396 1.2%   
Net working cap to sales %72.647.2 153.8%  
Current ratio x3.41.8 189.6%  
Inventory Days Days9999 100.2%  
Debtors Days Days24112 21.5%  
Net fixed assets Rs m244232,477 0.1%   
Share capital Rs m2272,399 9.5%   
"Free" reserves Rs m5,441411,691 1.3%   
Net worth Rs m5,668414,091 1.4%   
Long term debt Rs m2515,226 0.2%   
Total assets Rs m7,901646,938 1.2%  
Interest coverage x353.310.0 3,516.0%   
Debt to equity ratio x00 12.0%  
Sales to assets ratio x0.90.4 191.1%   
Return on assets %16.55.8 284.1%  
Return on equity %22.97.8 296.0%  
Return on capital %34.010.2 334.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1566,025 0.0%   
Fx outflow Rs m2,67738,610 6.9%   
Net fx Rs m-2,66227,415 -9.7%   
CASH FLOW
From Operations Rs m92321,965 4.2%  
From Investments Rs m317-6,813 -4.7%  
From Financial Activity Rs m-481-27,305 1.8%  
Net Cashflow Rs m759-8,442 -9.0%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 7.2 23.0 31.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 8.3 366.3%  
Shareholders   21,978 133,026 16.5%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS